Search This Blog

Tuesday, April 2, 2024

FDA accepts application for Astrazeneca-Daiichi breast cancer med

 Application based on results from the TROPION-Breast01 Phase III trial

Additional BLA under review in the US for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for patients with advanced nonsquamous non-small cell lung cancer

https://finance.yahoo.com/news/datopotamab-deruxtecan-biologics-license-application-110000638.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.